€ 6.58
Key Takeaways
Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
About
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is neutral on EV/EBITDA, overpriced on P/FC
Target Price
The average target price of EVT.DE is 10 and suggests 52% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
